Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report

20250 citationsJournal Articlegold Open Access

Authors

Jeremy Rosiecki · Alaska Oncology & Hematology

Natalie Wallace · Alaska Oncology & Hematology

Kai Kammers · Providence Alaska Medical Center

A. Cheng · Providence Alaska Medical Center

Tygh Wyckoff · Alaska Oncology & Hematology

Steven Liu · Alaska Oncology & Hematology

Abstract

T-cell engager therapies, such as epcoritamab, can play a role in managing patients with refractory DLBCL, including those refractory to CAR T-cell therapy.

Topics & Keywords

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research CNS Lymphoma Diagnosis and Treatment

Publication Details

Published in: Case Reports in Oncology

Volume 18, Issue 1, pp. 744-750

DOI: 10.1159/000545372

Field-Weighted Citation Impact: 0.00

Command Palette

Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report

Authors

Abstract

Topics & Keywords

Publication Details